✦ LIBER ✦

PCV68 COST-EFFECTIVENESS OF GENOTYPE-DRIVEN ANTIPLATELET THERAPY FOR SECONDARY PREVENTION AFTER ACUTE CORONARY SYNDROME

✍ Scribed by DJ Crespin; JJ Federspiel; AK Biddle; D Jonas; SC Stearns; JS Rossi

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ticagrelor versus Genotype-Driven Antipl

✍ Daniel J. Crespin; Jerome J. Federspiel; Andrea K. Biddle; Daniel E. Jonas; Jose 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 913 KB

COST-EFFECTIVENESS OF UNIVERSAL OR GENOT

✍ Soyon Lee; Asha Dhamija; Katelyn Parsons; Matthew King; Rajbir Kaur; Matthew Rob 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 91 KB

PCV74 ONE-YEAR COST-EFFECTIVENESS OF CYT

✍ SL Charland; B Agatep; D Malone; E Stanek 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

A Cost-Effectiveness Analysis of Combina

✍ M.D. Schleinitz; P.A. Heidenreich 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Long-term cost-effectiveness of early an

✍ Elizabeth M. Mahoney; Shamir Mehta; Yong Yuan; Joseph Jackson; Roland Chen; Sylv 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 163 KB